{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-230774","form_type":"8-K","ticker":"IRIX","cik":"0001006045","company_name":"IRIDEX CORP","filed_at":"2026-05-19T20:13:42+00:00","discovered_at":"2026-05-19T20:15:00.455276+00:00","generated_at":"2026-05-19T21:24:50.095407+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Iridex Q1 revenue $11.8M (-1% YoY); net loss narrows to $0.5M; Cyclo G6 up 14%","bullets":["Revenue $11.8M, down 1% YoY; Cyclo G6 product revenue $3.6M (+14% YoY) on 15,500 probes sold.","Net loss $0.5M ($0.03/sh) compared to $1.7M ($0.10/sh) in Q1 2025; Non-GAAP adjusted EBITDA $0.3M.","Gross margin 40% vs 43% a year ago, pressured by tariffs and transition to low-cost manufacturers.","Cash $4.6M; company expects positive cash flow for full year 2026 despite typical Q1 usage.","FY2026 revenue guidance reaffirmed at $51M-$53M; adjusted opex guided $19M-$19.5M."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-230774","json":"https://secwatch.observer/filing/0001193125-26-230774.json","markdown":"https://secwatch.observer/filing/0001193125-26-230774.md","text":"https://secwatch.observer/filing/0001193125-26-230774.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1006045/000119312526230774/0001193125-26-230774-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1006045/000119312526230774/irix-20260519.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T21:24:50.095407+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"06edacf3fa8d650476e7550c49de10695f9c8c59","claim":"IRIDEX CORP reported first quarter ended April 4, 2026 results: revenue $11.8 million, net income $0.5 million or $0.03 per share, EPS $0.03 per share. Guidance reaffirmed.","evidence_excerpt":"glaucoma and retinal diseases, today reported financial results for the first quarter ended April 4, 2026. First Quarter 2026 Financial Highlights • Generated total revenue of $11.8 million, compared to $11.9 million in the prior year period • Cyclo G6® product family revenue was $3.6 million, representing growth of 14% year-over-year compared to $3.2 million in the","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1006045/000119312526230774/0001193125-26-230774-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended April 4, 2026"},{"label":"Revenue","value":"$11.8 million"},{"label":"Net income","value":"$0.5 million or $0.03 per share"},{"label":"EPS","value":"$0.03 per share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}